X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://investors.barinthusbio.com/news-releases/news-release-details/barinthus-bio-announces-topline-data-phase-1b2-apollo-trial-vtp
https://www.globenewswire.com/news-release/2024/04/18/2865826/0/en/Barinthus-Bio-Announces-Topline-Data-from-Phase-1b-2-APOLLO-Trial-of-VTP-200-in-Persistent-High-Risk-Human-Papillomavirus-HPV-Infections.html
https://www.globenewswire.com/news-release/2024/03/20/2849345/0/en/Barinthus-Bio-Reports-Full-Year-2023-Financial-Results-and-Update-on-Corporate-Developments.html
https://www.globenewswire.com//news-release/2024/01/05/2804866/0/en/Barinthus-Bio-Provides-a-Financial-Update-and-Announces-Anticipated-2024-Corporate-Milestones.html
https://www.fiercebiotech.com/biotech/barinthus-new-mission-gets-35m-booster-cepi-funding-develop-mers-shot
https://www.globenewswire.com//news-release/2023/12/21/2799930/0/en/New-partnership-aims-to-advance-vaccine-against-MERS-coronavirus.html
https://www.fiercebiotech.com/biotech/vaccitech-re-emerges-barinthus-hep-b-data-showing-decline-level-infection
https://www.globenewswire.com//news-release/2023/11/06/2774201/0/en/Vaccitech-Renames-as-Barinthus-Biotherapeutics-to-Highlight-Strategic-Evolution-into-a-T-Cell-Immunotherapy-Company-Targeting-Chronic-Infectious-Diseases-Autoimmunity-and-Cancer.html
https://www.globenewswire.com/news-release/2023/08/10/2722631/0/en/Vaccitech-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Developments.html
https://www.globenewswire.com/news-release/2023/06/12/2686194/0/en/Vaccitech-Doses-First-Patient-in-PCA001-a-Prostate-Cancer-Phase-1-2-Clinical-Trial-of-VTP-850-Immunotherapeutic-Candidate-in-Men-with-Rising-PSA-after-Definitive-Local-Therapy.html
Market Place
Share 
